EP2467129A1 - Granulat von verbesserter löslichkeit und stabilität - Google Patents

Granulat von verbesserter löslichkeit und stabilität

Info

Publication number
EP2467129A1
EP2467129A1 EP10801007A EP10801007A EP2467129A1 EP 2467129 A1 EP2467129 A1 EP 2467129A1 EP 10801007 A EP10801007 A EP 10801007A EP 10801007 A EP10801007 A EP 10801007A EP 2467129 A1 EP2467129 A1 EP 2467129A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
ramipril
mixture
pharmaceutically acceptable
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10801007A
Other languages
English (en)
French (fr)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bilgic Mahmut
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2467129A1 publication Critical patent/EP2467129A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the present invention relates to pharmaceutical compositions with improved solubility and stability comprising ramipril alone or in combination with a therapeutic agent like HCTZ, the preparation methods of these compositions and their medical usages.
  • the present invention provides a composition which is effective for the treatment of hypertension and congestive heart failure and for the reduction in mortality risk relative to paralysis, cardiovascular and myocardial infarction.
  • This effect provided by the composition that is prepared in accordance with the invention is named as "desired effect" during the patent.
  • composition comprises ramipril as an antihypertensive agent alone or in combination with hydrochlorothiazide (HCTZ) which is a diuretic.
  • HCTZ hydrochlorothiazide
  • renin-angiotensin system has proved to be the most suitable method for the treatment of hypertension and congestive heart failure and the reduction in mortality risk relative to paralysis, cardiovascular and myocardial infarction.
  • angiotensin converting enzyme (ACE) inhibitors like ramipril are commonly preferred.
  • Said drugs can be combined with other therapeutic agent and/or agents for the increasing effectiveness.
  • an angiotensin II (AT-II) receptor antagonist which is also used as renin-angiotensin system inhibitor
  • AT-II angiotensin II
  • HCTZ the diuretics like HCTZ also increase the effectiveness of ACE inhibitors.
  • Ramipril is an angiotensin converting enzyme (ACE) inhibitor that is used to treat hypertension and congestive heart failure.
  • Ramipril is an inactive prodrug and is converted to the active metabolite ramiprilate in the liver.
  • AT-II is synthesized from AT-I by a reaction catalyzed by ACE.
  • Ramipril competes with AT-I for binding to ACE and blocks the conversion of AT-I to AT-II.
  • AT-II has some effects such as vasodilation, stimulation of the production and secretion of aldosterone, cardiac stimulation and the increase in the reabsorption of sodium from kidney tubulus.
  • HCTZ is a thiazide derivative diuretic with a chemical name of 6-chloro-3,4-dihydro-2H- l,2,4-benzothiadiazine-7-sulfonamide 1,1 -dioxide. (Formula II).
  • HCTZ has been firstly described in the patent numbered US3025292. In the patent, there are processes to prepare HCTZ.
  • HCTZ is a thiazide derivative diuretic which is used in the treatment of edema and hypertension.
  • Thiazide derivative diuretic increases elimination of sodium, chloride and water by inhibing the passage of sodium from kidney tubulus.
  • the diuretic effect of HCTZ indirectly decreases the plasma volume with the elevations of plasma renin activity, aldosterone secretion and loss of urinary potassium and with the decreases of serum potassium level.
  • the connection of renin-aldosterone comes through angiotensin II. For this reason, the use of diuretics with angiotensin II receptor antagonist has a tendency to reverse potassium loss caused by diuretics.
  • Thiazides generally do not influence blood pressure.
  • the present invention is related to obtaining pharmaceutical compositions which have rampril alone or in combination with therapeutic agents like HCTZ and provides the desired effect.
  • an aspect of the invention is to formulate this agent as a pharmaceutical form like tablet by providing a formulation in accordance with the invention comprising a pharmaceutically acceptable, non-toxic and therapeutically effective amount of rampril.
  • Said composition can further comprise pharmaceutically acceptable, non-toxic and therapeutically effective amount of HCTZ.
  • the prodrugs that are used orally should be designed in a way that increase the oral bioavailability of the drug and enable the drug reach the target. However, in the mean time the biological activity should be protected. For this purpose, the oil solubility, water solubility, partition coefficient and stability of the drug should be optimized.
  • Prodrugs that are used orally are classified as salts having low solubility, the oil soluble (lipophilic) prodrugs including esters or complexes, the water soluble prodrugs including highly soluble salts, esters or complexes.
  • the diffusion coeeficient which depends on the oil-solubility of the drug plays an important role in the inhibition of ACE. Therefore, the most common method used for increasing the oil-solubility of the drug is the usage of the lipophilic esters whose ester part diffuses into tissues much easily.
  • the water-solubility of the lipophilic esters is low, thus their oral bio-avaliability is low.
  • Ramipril is also a lipophilic ester having low water-solubility.
  • nanoparticle technology Another method used for increasing surface area of the drug is nanoparticle technology.
  • this technology faces some problems such as the technical and mechanical restraints preventing the drug particles from breaking into nanoparticles and problems like the stabilization of quite small drug particles.
  • the patent applications numbered US20080188539 Al, US20080171775 Al and US20080167364 Al are respectively related to; the capsules that are composed of micro- tablets including a ACE inhibitor, the controlled release formulations comprising microcapsules, fast disintegrating ramipril formulations and ramipril formulations comprising a controlled release agent, respectively.
  • the patent applications increase bioavailability of drug by changing its release properties in the applications.
  • changing the release properties only for improving tableting properties is not a preferable method.
  • Another method used for increasing absorption, thus bio-availability is to use the additional substances like absorption increasing agent and metabolism inhibitor.
  • absoption enhancers can cause mucosal damage and systemic toxicity.
  • Ramipril faces with stability problem in addition to the solubility problem.
  • the formulations comprising ramipril tend to degrade when exposed to heat, light, air, moisture and mechanic effect, in unsuitable conditions and as a consequence of some interactions.
  • the patent application numbered WO2004064809 Al is related to the pharmaceutical compositions having low moisture content that are composed of ramipril and/or a salt and at least one excipient.
  • the patent application numbered WO2008000040 Al is related to the pharmaceutical compositions comprising an ACE inhibitor or a salt, a basic stabilizing agent, auxiliary agents and also moisture controller substances.
  • Another preferable method for increasing stability is to add into the composition some substance that will slow down or decrease the degradation of the composition.
  • the patent applications numbered WO2003028707 Al , US2005069586 Al, WO2008132756 Al, WO9962560 A1, US20060188568 Al, US20080038342 Al and US20080234353 Al are related to the formulations comprising lactose monohydrate, a lubricant, lactic acid with magnesium salts, hydrolysis minimizing agent with magnesium oxide, meglumine, a Ci6-C 2 8 glyceride and sodium hydrogen carbonate with calcium sulfate dihydrate, respectively.
  • HCTZ is a substance that can be dissolved in aqueous solutions easily. However, it is incompatible with basic agents. Therefore, for the combination of ramipril and HCTZ, in addition to the stability and solubility problems of ramipril the incompatibility between the substances forming the composition emerges. Because, when basic agents increasing ramipril stability interact with HCTZ, it leads to incompatibility. Due to the incompatibility, the stability problem is observed in the tablets. In current state of the art, there are some formulation suggestions about the combination of ramipril and HCTZ.
  • the patent application numbered US20070116762 Al is related to pharmaceutical compositions including rampril coated by a blending agent and HCTZ as an active agent.
  • WO2008001 184 A2 is related to pharmaceutical compositions containing a ACE inhibitor in blended or pellet form and a diuretic in tablet form .
  • solubility problem of ramipril is not considered. Therefore, it is necessary to search for new methods aimed at solving both the solubility and stability problems of ramipril and prevent a probable compatibility problem in case HCTZ is included in the formulation.
  • the present invention presents a new composition for formulating ramipril without any solubility or stability problems or combining ramipril and HCTZ without any incompatibility problem and an uncomplicated production method.
  • the present invention is related to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of ramipril alone or in combination with a therapeutically effective amount of HCTZ for use in the production of an effective drug for the treatment of hypertension and congestive heart failure and the reduction in mortality risk relative to paralysis, cardiovascular and myocardial infarction, characterized in that in said pharmaceutical composition the microcrystalline cellulose granules are coated by a coating solution which comprises ramipril dissolved said solution and that it has improved solubility and stability properties.
  • the method for the preparation of pharmaceutical formulations which are suitable for the present invention and include ramipril alone, contains the following steps:
  • the granulation solution is obtained by dissolving ramipril in pharmaceutically acceptable binding agents chosen from an alcohol, ketone, cellulose derivative, water or a mixture of them, more preferably 1-propanol, 2-propanol, ethyl alcohol, acetone, HPMC, water or a pure solvent or solvent mixture which is a mixture of them;
  • pharmaceutically acceptable binding agents chosen from an alcohol, ketone, cellulose derivative, water or a mixture of them, more preferably 1-propanol, 2-propanol, ethyl alcohol, acetone, HPMC, water or a pure solvent or solvent mixture which is a mixture of them;
  • the granules coated with ramipril is obtained by spraying the granulation solution mentioned in Step 1 on microcrystalline cellulose in the fluidized-bed granulator;
  • the granules dried and sieved in Step 3 are mixed with at least one pharmaceutically acceptable excipient preferably chosen from binding agent, diluent, dispersing agent, glidant and stabilizing agents;
  • the mixture obtained in Step 4 is preferably mixed with a pharmaceutically acceptable surfactant
  • Step 6 The mixture obtained in Step 5 is fed to tablet pressing machine and the tablets are compressed in accordance with tablet specifications;
  • the tablets obtained in Step 6 are preferably coated by film coating.
  • the method for the preparation of the pharmaceutical formulations in accord with the present invention comprising ramipril and HCTZ is a two-stage method where in the first stage comprises the five steps given above, the second stage comprises the following steps:
  • HCTZ is mixed with at least one pharmaceutically acceptable excipient preferably chosen from diluent, dispersing agents, glidant and stabilizing agents and sieved;
  • a pharmaceutically acceptable surfactant is added to the mixture obtained in Step 6 and mixed;
  • the mixture obtained by mixing the mixtures from Step 5 and 7, is fed to the tablet pressing machine or each mixture is fed to the tablet pressing machine separately for obtaining a layered tablet;
  • the tablets obtained in Step 8 are preferably covered by film coating.
  • the present invention is related pharmaceutical compositions which contain ramipril alone or in combination with a therapeutic agent like HCTZ and provide the desired effect.
  • a therapeutic agent like HCTZ a therapeutic agent like HCTZ
  • both solubility and stability problems are faced in the formulation studies including only ramipril.
  • a probable incompatibility of the components forming the composition arises and thus a probable stability problem constitutes a risk.
  • the solubility and stability problems of ramipril and the incompatibility problem of the substances forming the composition should be solved by an incomplicated method so that the compositions comprising rampril alone or in combination with a therapeutic agent like HCTZ can provide the desired effect.
  • pharmaceutically effective amount of active compound/compounds and suitable amount of excipients should be found.
  • a pharmaceutical composition including the granules obtained by applying a manufacturing process in which microcrystalline cellulose is coated by a coating solution comprising dissolved ramipril, has both improved solubility and stability properties and provides the desired effect.
  • the first aspect of the invention is to obtain the diluent granules coated by a coating solution comprising dissolved ramipril.
  • the pharmaceutical compositions according to the invention comprise microcrystalline cellulose as a diluent to be coated.
  • the microcrystalline cellulose which is stable, reliable and physiologically inert becomes compact quickly at the minimum pressure. This feature provides an opportunity for pressing tablets without being exposed to a high pressure. Microcrystalline cellulose makes tablets stiff. As a result of these features, the tendency of ramipril degradation under mechanic effect is kept under control.
  • the binding and carrying capacity of microcrystalline cellulose are high. This way, it can carry ramipril particules without any agglomeration by binding the ramipril solution which is coated on it.
  • the second aspect of the invention is to obtain a suitable pure solvent or solvent mixture in which ramipril can dissolve before coating it on the microcrystalline cellulose and thus increase the solubility of ramipril. While ramipril tends to agglomerate, the granules which are obtained by spraying the granulation solution (coating solution) including ramipril, which is dissolved in a suitable pure solvent or solvent mixture on microcrystalline cellulose and then dried so as to have maximum 1.5 % moisture ratio and sieved, have represented a solubility of > 98 % at the first 5 minutes in a dissolution medium that is suitable for ramipril.
  • Pure solvent or solvent mixture that is according to the present invention is chosen from pharmaceutically acceptable binding agents, preferably, it is an alcohol, ketone, cellulose derivative, water or a suitable mixture of them, more preferably 1-propanol, 2-propanol, ethyl alcohol, acetone, HPMC, water or a suitable mixture of them.
  • the third aspect of the invention is to determine a suitable excipient composition and manufacturing method in order to further improve the solubility and stability features of the granules that were obtained with improved solubility and stability features. Considering the probability of degradation of ramipril, preferably pregelatinized starch, which is resistant to moisture and mechanic effect, is added to the microcrystalline cellulose granules covered by ramipril solution.
  • Photo- protector like iron oxide as stabilizing agent can be used at this stage for the pharmaceutical compositions in accord with the invention comprising ramipril alone, and can be used at the stage of the preparation of the second mixture which will be between two compositions for the pharmaceutical compositions in accord with the invention including ramipril in combination.
  • the fourth aspect of the invention is to develop an incomplicated manufacturing procedure where active components are formulated seperately to prevent a probable incompatibility problem in the event of adding HCTZ to the formulation and to choose suitable excipients.
  • two seperate formulations including ramipril and HCTZ and two separate manufacturing procedures are developed.
  • No basic excipient is added to the mixture in which HCTZ is formulated.
  • the use of the excipients which is included in the first mixture is tried in terms of compatibility and no stability problems were observed. This way, taking into account the advantages mentioned previously and the fact that no compatibility problems were observed preferably microcrystalline cellulose, pregelatinized starch or colloidal silicon dioxide are added to the said mixture.
  • the fifth aspect of the invention is to decide on the lubricant that will be added to the mentioned mixture or mixtures as the last excipient.
  • Said lubricant should be a kind of substance that does not delay spreading, is not affected by the blending time, does not cause degradation under mechanic effect and does not affect stability adversely.
  • the pharmaceutical compositions in accord with the invention preferably comprise sodium stearil fumarate as lubricant to meet all these needs.
  • the preparation method of the pharmaceutical compositions in accord with the invention including ramipril alone includes the following steps:
  • the granulation solution is obtained by dissolving ramipril in a solvent chosen from pharmaceutically acceptable binding agents, preferably in an alcohol, ketone, cellulose derivative, water or a mixture of them, more preferably 1-propanol, 2-propanol, ethyl alcohol, acetone, HPMC, water or a pure solvent or solvent mixture which is a mixture of them.
  • a solvent chosen from pharmaceutically acceptable binding agents, preferably in an alcohol, ketone, cellulose derivative, water or a mixture of them, more preferably 1-propanol, 2-propanol, ethyl alcohol, acetone, HPMC, water or a pure solvent or solvent mixture which is a mixture of them.
  • the granules coated by ramipril are obtained by spraying the granulation solution mentioned in Step 1 onto microcrystalline cellulose in the fluidized-bed granulator.
  • the granules obtained in Step 2 are dried and sieved. 4.
  • the granules dried and sieved in Step 3 are mixed with at least one pharmaceutically acceptable excipient chosen from preferably binder, diluent, dispersing agent, glidant and stabilizing agents.
  • a pharmaceutically acceptable lubricant is added to the mixture obtained in Step 4 and mixed.
  • Step 5 The mixture obtained in Step 5 is fed to tablet pressing machine and the tablets are compressed in accordance with their specifications.
  • the tablets obtained in Step 6 are preferably coated by film coating.
  • the method for the preparation of the pharmaceutical formulations in accord with the present invention comprising ramipril and HCTZ has two stages.
  • the preparation stage of the first mixture containing ramipril has the first five steps describe above.
  • the preparation stage of the second mixture including HCTZ has the following steps:
  • HCTZ is mixed with at least one pharmaceutically acceptable excipent preferably chosen from diluent, dispersing agent, glidant and stabilizing agents and sieved;
  • a pharmaceutically acceptable lubricant is preferably added to the mixture obtained in Step 6 and mixed;
  • the resultant mixture obtained by mixing the mixtures from Step 5 and 7, is fed to the tablet pressing machine or each mixture is fed to the tablet pressing machine separately for obtaining a layered tablet;
  • the tablets obtained in Step 8 are preferably coated by film coating.
  • the sixth aspect of the invention is to determine the suitable composition comprsing ramipril in a certain ratio and in case of combination a certain ratio of HCTZ and at least one pharmaceutically acceptable excipient chosen from the additives like binder, diluent, dispersant, glidant, stabilizing agent and lubricant for obtaining the desired therapeutical effectiveness.
  • the pharmaceutically acceptable binding agents can be chosen from a group comprising starch (such as patato starch, corn starch, wheat starch); the sugars like sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic resins (like accacia), gelatin, cellulose derivatives (such as microcrystalline cellulose, HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose, ethylcellulose), polyvinylpyrrolidone, polyethylene glycol, waxes, calcium carbonate, calcium phosphate, alcohols (such as sorbitol, xylitol, mannitol) and water.
  • starch such as patato starch, corn starch, wheat starch
  • sugars like sucrose, glucose, dextrose, lactose, maltodextrin
  • natural and synthetic resins like accacia
  • gelatin such as microcrystalline cellulose, HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose,
  • the pharmaceutical compositions in accordance with the invention preferably includes an alcohol, ketone, cellulose derivative, water or a suitable mixture of them, more preferably 1-propanol, 2-propanol, ethyl alcohol, acetone, HPMC, water or a suitable mixture of them as binding agent.
  • the solid binding agents are present in the pharmaceutical composition in an amount up to 10% by weight.
  • liquid binding agents are added to the composition in sufficient amounts.
  • the pharmaceutically acceptable diluents can be chosen from lactose, microcrystalline cellulose, starch, pre-gelatinized starch, modified starch, calcium phosphate (dibasic and/or tribasic), calcium sulfate trihydrate, calcium sulfate dihydrate, calcium carbonate, kaolin, lactilol, powdered cellulose, dextrose, dextrates, dextrin, sucrose, maltose, fructose, mannitol, sorbitol and xylitol.
  • the pharmaceutical compositions in accord with the invention preferably contain microcrystalline cellulose as a diluent to be coated on.
  • Said pharmaceutical compositions optionally include at least one more diluent chosen from the group described above.
  • the diluent is present in the composition in an amount up to 85% by weight.
  • the pharmaceutically acceptable dispersing agents can be chosen from starch (corn starch, patato starch), sodium starch glycolate, pre-gelatinized starch, cellulose derivatives (such as croscarmellose sodium or microcrystalline cellulose), polyvinylpyrrolidone, crospovidon, alginic acid, soldium alginate, clays (like xanthan gum or Veegum), ion-exchange resins effervescent systems, based on food acids and alkali carbonate compounds.
  • the pharmaceutical compositions according to the invention preferably includes pre-gelatinized starch as dispersing agent.
  • the dispersing agent is present in the composition in an amout up to 85% by weight.
  • the pharmaceutically acceptable glidants can be chosen from silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talk, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfates.
  • the pharmaceutical compositions according to the invention preferably include silicon dioxide as gilidant. The glidant is present in the composition in an amount lower than 1% by weight.
  • the pharmaceutically acceptable stabilizing agent or agents can be chosen from among some agents such as antioxidants, chelating agents, alkalinizing agents and photo-protectors.
  • the pharmaceutical compositions according to the invention preferably includes iron oxide as stabilizing agents.
  • the stabilizing agent or agents is present in the composition in an amount up to 10% by weight.
  • Antioxidants can be chosen from some substances such as butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium sulfite, gallates (like propil gallates), tocoferole, citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbil palmitate, ethylenediamine tetraacetate.
  • Chelating agents can be chosen from disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or their combinations.
  • Alkalinizing agents can be chosen from the organic compounds such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, alkali metal salts like sodium aluminate; calcium carbonate, calcium hydroxide, dibasic calcium phosphate, calcium sulfate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulfate, magnesium acetate, magnesium silicate, the alkaline earth metal salts like magnesium aluminate, primary, secondary and tertiary amines, cyclic amines, ⁇ , ⁇ '- dibenzylethylenediamin, dietanolamine, ethylenediamin, meglumine, monosodium glutamate, polacrilin sodium, sodium alginate.
  • organic compounds such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, alkali metal salts like sodium
  • Photo-protecting agents can be chosen from metal oxides such as titanium oxide, iron oxide or zinc oxide
  • the pharmaceutically acceptable lubricants can be chosen from metallic stearates (such as magnesium stearate, calcium stearate, aluminium stearate), fatty acid esters (like sodium stearyl fumarate), fatty acids (like stearic acid), fatty alcohols, glyceril behenate, mineral oil, paraffines, hydrogen vegetable oil, leucine, polyethylene glycols, metallic lauryl sulfates (such as sodium lauryl sulfate, magnesium lauryl sulfate), sodium chloride, sodium benzoate, sodium acetate and talk.
  • the pharmaceutical compositions according to the invention preferably include sodium stearyl fumarate as lubricant.
  • the lubricant is preferably present in the composition in an amount up to 10% by weight.
  • Example 1 The pharmaceutical composition comprising 2.5 mg ramipril
  • Example 2 The pharmaceutical formulation comprising 5 mg ramipril
  • Example 3 The pharmaceutical formulation comprising 10 mg ramipril
  • Example 4 The pharmaceutical composition comprising 2.5 mg ramipril / 12.5 mg HCTZ
  • Example 5 The pharmaceutical composition comprising 2,5 mg ramipril / 25 mg HCTZ
  • Example 6 The production method of pharmaceutical formulation comprising 5 mg ramipril
  • the granulation solution is obtained by dissolving 2,5 mg ramipril and 2,0 mg HPMC in a mixture comprising 25,0 mg 1-propanol and 10.0 mg deionized water.
  • the granules coated by ramipril is obtained by spraying the granulation solution mentioned above onto 74.2 mg microcrystalline cellulose in fludized bed granulator.
  • Dried and sieved granules is mixed with 15.0 mg pregelatinezed starch,4.0 mg HPMC 0.2 mg iron oxide, and 0.1 mg colloidal silicone dioxide.
  • Example 7 The production method of pharmaceutical composition comprising 2.5 mg ramipril/ 12.5 mg HCTZ - The granulation solution is obtained by dissolving 2,5 mg ramipril in a mixture comprising 25,0 mg 2-propanol and 10.0 mg deionized water.
  • the granules coated by ramipril is obtained by spraying the granulation solution mentioned above onto 7,5 mg microcrystalline cellulose in fludized bed granulator.
  • Granules obtained is dried so as to have maximum 1.5% moisture ratio and sieved.
  • the first mixture is obtained by adding 0.5 mg sodium stearyl fumarate to the obtained mixture and mixing
  • the second mixture is obtained by adding 0.5 mg sodium stearyl fumarate to the obtained mixture and mixing.
  • the resultant mixture obtained by mixing the obtained mixtures is fed to the tablet pressing machine or both mixtures are fed to the tablet pressing machine separately to get a layered tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10801007A 2009-08-17 2010-08-13 Granulat von verbesserter löslichkeit und stabilität Withdrawn EP2467129A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2009/06322A TR200906322A2 (tr) 2009-08-17 2009-08-17 Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
PCT/TR2010/000167 WO2011034513A1 (en) 2009-08-17 2010-08-13 The granules with improved solubility and stability

Publications (1)

Publication Number Publication Date
EP2467129A1 true EP2467129A1 (de) 2012-06-27

Family

ID=43568838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10801007A Withdrawn EP2467129A1 (de) 2009-08-17 2010-08-13 Granulat von verbesserter löslichkeit und stabilität

Country Status (3)

Country Link
EP (1) EP2467129A1 (de)
TR (1) TR200906322A2 (de)
WO (1) WO2011034513A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163579B2 (en) * 2004-04-14 2007-01-16 H.B. Fuller Licensing & Financing Inc. Method of making water resistant corrugated boards

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3025292A (en) 1962-03-13 Reduction of i
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
WO1999062560A1 (en) 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
US20030225124A1 (en) 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
CA2357982A1 (en) 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
EA007981B1 (ru) 2002-01-15 2007-02-27 Актавис Груп Хф. Фармацевтический состав, содержащий хинаприл или фармацевтически приемлемую его соль
EP1467717A1 (de) 2002-01-15 2004-10-20 Ranbaxy Laboratories Limited Stabile pharmazeutische zusammensetzungen mit ace-inhibitor(en)
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
EP1653929A1 (de) 2003-01-22 2006-05-10 Sandoz AG Feste pharmazeutische zusammensetzung mit ramipril
MXPA06000226A (es) * 2003-06-26 2006-03-21 Teva Pharma Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3..0]-octano-3-carboxilico.
GB2404336A (en) 2003-07-30 2005-02-02 Cipla Ltd Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof
AU2003300692A1 (en) 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US20080234353A1 (en) 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
US20060045911A1 (en) 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
JP2008519062A (ja) 2004-11-05 2008-06-05 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド 個々に被覆された安定化ラミプリル粒子、組成物及び方法
WO2007056442A1 (en) 2005-11-07 2007-05-18 King Pharmaceuticals Research & Development, Inc. Compositions of stabilized ramipril in combination with another active agent
WO2008001184A2 (en) 2006-06-26 2008-01-03 Emcure Pharmaceuticals Limited Solid composition
WO2008000040A1 (en) 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ace inhibitors
GB0624087D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
PL382311A1 (pl) 2007-04-27 2008-11-10 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna o polepszonej stabilności zawierająca inhibitor acetylocholinoesterazy lub farmaceutycznie dopuszczalną jego sól oraz sposób jej wytwarzania
WO2008132756A1 (en) 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011034513A1 *

Also Published As

Publication number Publication date
WO2011034513A1 (en) 2011-03-24
TR200906322A2 (tr) 2011-07-21

Similar Documents

Publication Publication Date Title
US20050186274A1 (en) Multilayer tablet
JP4606166B2 (ja) テルミサルタンを含有する新規固形医薬調合物およびその調製方法
JP2023011888A (ja) 新たな医薬組成物
JP5295123B2 (ja) 新規医薬組成物
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
JP2013082754A (ja) テルミサルタン及び利尿剤を含有する二層錠剤
JP7094944B2 (ja) ロスバスタチン及びエゼチミブを含む医薬組成物並びにその調製方法
JP2008515838A (ja) ２層錠剤
JP2682353B2 (ja) 経口用医薬組成物およびその製造法
EP1429748B1 (de) Feste zubereitungen mit ramipril
CN102088972B (zh) 含有咪唑-5-羧酸类衍生物的药用组合物,其制备方法及用途
CA3085455C (en) A solid oral dosage form comprising linagliptin
EP3886817A1 (de) Pharmazeutische zusammensetzung mit ramipril und indapamid
EP4373474A1 (de) Zweischichtige tablette mit telmisartan und indapamid
HK1205683A1 (en) Pharmaceutical formulation having improved stability
EP4079296A1 (de) Zweischichtige tablettenformulierung mit amorphem dapagliflozin und metformin
WO2011034513A1 (en) The granules with improved solubility and stability
EP2638898A1 (de) Metformin- und Pioglitazonformulierung mit verschiedenen Freisetzungsprofilen
JP2009533461A (ja) ２−アザ−ビシクロ［３．３．０］−オクタン−３−カルボン酸誘導体の安定な医薬組成物
WO2008045006A1 (en) Formulations of candesartan
US11865215B2 (en) Tablet compositions comprising abiraterone acetate
CN112957336A (zh) 一种稳定的坎地沙坦酯药物固体组合物及其制备方法
JPH10226644A (ja) 医薬組成物
US20090226516A1 (en) Sartan compositions
RU2479310C2 (ru) Фармацевтическая композиция для лечения артериальной гипертензии и застойной сердечной недостаточности и способ ее получения

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BILGIC, MAHMUT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BILGIC, MAHMUT

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140301